Physician profile
Devanshi Patel
NPI 1396434197
$580.25
in general payments reported to CMS, 2019-2025
15 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $153 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $216.27 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $78.72 | 2024-2025 | |
| Janssen Biotech, INC. | $49.72 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Curonix LLC | $33.01 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Eisai INC. | $31.57 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.81 | 2025 | Iclusig |
| Invivyd INC | $18.68 | 2025 | Pemgarda |
| Deciphera Pharmaceuticals INC. | $18.38 | 2025 | Qinlock, Romvimza |
| Kyowa Kirin, INC. | $18.28 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.45 | 2025 | Opdivo |
| Pharmaessentia USA Corporation | $16.38 | 2025 | Besremi |
| Servier Pharmaceuticals LLC | $16.37 | 2024 | |
| Lilly USA, LLC | $16.03 | 2024 | Jaypirca, Verzenio |
| Alexion Pharmaceuticals, INC. | $15.85 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $14.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devanshi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.